Screening in HPV related cancers

Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 351

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

DTOGIMED03_011

تاریخ نمایه سازی: 26 بهمن 1398

Abstract:

Cervical cancerHPV 16/18 genotyping as a primary screening method for cervical cancer appears to be one of themost effective strategies and dominates current practice in respect to both cost and outcomes. Evenwhen compared with all other strategies, the outcomes that it generates justify the cost that itrequires, representing a good value for money alternative.Anal cancerAlthough anal squamous cell carcinoma (SCC) and adenocarcinoma (ADC) are generally combinedin cancer surveillance, their etiologies likely differ .Women had higher rates of anal SCC and CIS haveincreased strongly over time. Strong increases in CIS over time may reflect anal cancer screeningpattern.While there are no data yet to demonstrate that identification and treatment of anal HSIL leads toreduced risk of anal cancer, women in groups at the highest risk should be queried for anal cancersymptoms and required to have digital anorectal examinations to detect anal cancers. Humanimmunodeficiency virus-infected women and women with lower genital tract neoplasia may beconsidered for screening with anal cytology with triage to treatment if HSIL is diagnosed. Healthywomen with no known risk factors or anal cancer symptoms do not need to be routinely screenedfor anal cancer or anal HSILThere is no consensus on screening strategy of high-grade intraepithelial neoplasia (HGAIN).Guidelines range from clinical examination with digital anorectal examination followed by standardanoscopy (SA), to anal cytology (Pap)+/- HPV genotypingOropharyngeal cancerIncidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing. There isinterest in identifying healthy individuals most at risk for development of oropharyngeal cancer.Oncogenic oral HPV DNA is detected in 3.5% of all adults age 20-69 years. Screening strategies basedupon oncogenic oral HPV detection would be challenging. Most groups have low oncogenic oral HPVprevalence. In addition to the large numbers of individuals who would need to be screened toidentify prevalent oncogenic oral HPV, the lifetime risk of developing oropharyngeal caner amongthose with infection remains low.

Authors

Fariba Behnamfar

Gyn.Oncology Fellowship Esfahan University of Medical Sciences